EMEA’s CHMP Recommends Approval For Avastin In Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Renal cell cancer would be the fourth indication gained in the EU for the VEGF-inhibitor; Genentech plans to submit an sBLA for kidney cancer in 2008.
You may also be interested in...
FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5
ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.
EMEA’s CHMP Recommends Approval Of Avastin In Metastatic Breast Cancer
Committee also issues positive opinion for Roche’s Xeloda in first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.